BNP Paribas Financial Markets Increases Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

BNP Paribas Financial Markets grew its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 1,128.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 259,245 shares of the company's stock after purchasing an additional 238,146 shares during the period. BNP Paribas Financial Markets owned about 0.30% of Syndax Pharmaceuticals worth $3,427,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in SNDX. Algert Global LLC grew its holdings in shares of Syndax Pharmaceuticals by 65.4% during the 4th quarter. Algert Global LLC now owns 785,632 shares of the company's stock worth $10,386,000 after purchasing an additional 310,634 shares during the period. Nantahala Capital Management LLC lifted its position in shares of Syndax Pharmaceuticals by 23.7% in the fourth quarter. Nantahala Capital Management LLC now owns 560,532 shares of the company's stock valued at $7,410,000 after acquiring an additional 107,300 shares in the last quarter. Northern Trust Corp increased its stake in Syndax Pharmaceuticals by 7.5% in the fourth quarter. Northern Trust Corp now owns 792,750 shares of the company's stock valued at $10,480,000 after purchasing an additional 55,144 shares during the last quarter. Propel Bio Management LLC boosted its position in shares of Syndax Pharmaceuticals by 37.5% in the fourth quarter. Propel Bio Management LLC now owns 183,259 shares of the company's stock worth $2,423,000 after buying an additional 50,000 shares during the period. Finally, Virtus ETF Advisers LLC boosted its position in shares of Syndax Pharmaceuticals by 18.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock worth $70,000 after buying an additional 827 shares during the period.

Syndax Pharmaceuticals Stock Down 0.3%

SNDX traded down $0.03 during mid-day trading on Monday, reaching $9.02. 738,039 shares of the company traded hands, compared to its average volume of 1,721,221. The stock has a market capitalization of $776.14 million, a P/E ratio of -2.48 and a beta of 0.82. The company's fifty day moving average price is $12.10 and its 200-day moving average price is $14.03. Syndax Pharmaceuticals, Inc. has a 52-week low of $8.58 and a 52-week high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.06. The company had revenue of $20.04 million for the quarter, compared to the consensus estimate of $15.88 million. During the same period last year, the company earned ($0.85) EPS. The firm's revenue for the quarter was up 1900.0% on a year-over-year basis. As a group, sell-side analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on SNDX shares. HC Wainwright restated a "buy" rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. Guggenheim reiterated a "buy" rating and issued a $32.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 6th. Citigroup decreased their price objective on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. JPMorgan Chase & Co. lifted their price target on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a research note on Thursday, March 20th. Finally, Scotiabank boosted their price target on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a "sector perform" rating in a research report on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat, Syndax Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $35.91.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).